



Virtual Conference Managing Initial and Interim Reference Materials (IRM) for Relative Potency

June 24-28, 2024

All times are in Pacific Standard Time

Day 1 | Monday, June 24

Workshops: Day 1

- 7:00** Workshop 1: Overview of Reference Material Programs
Nadine Ritter, President, Global Biotech Experts
- 9:30** Break ☕
- 12:00** Workshops Conclude

Day 2 | Tuesday, June 25

Session Topic: Challenges With The First Relative Potency IRM

- 7:00** BEBPA Opening Remarks
Laurie Little, President, BEBPA
- 7:15** Conference Opening Remarks
Nadine Ritter, President, Global Biotech Experts
- 7:30** Regulatory Perspectives: First Vaccine Relative Potency IRM
FDA Invited Speaker, CBER, Office of Vaccines Research & Review
- 8:15** Regulatory Perspectives: First Therapeutic Relative Potency IRM
FDA Invited Speaker, CDER, Office of Therapeutic Biologics and Biosimilars
- 9:00** Break and Audience Survey ☕
- 9:15** Industry Case Study: First Vaccine Relative Potency IRM
Industry Invited Speaker
- 10:00** Building a Foundation for Success: Establishment and Management of Relative Potency Reference Material during Early Development
Ken Miller, Director, BioMarin Pharmaceutical Inc.
- 10:45** Break ☕
- 11:00** Panel Discussion with Q&A
- 12:45** Closing Remarks
Nadine Ritter, President, Global Biotech Experts
- 12:00** Virtual Conference Adjourns

Day 3 | Wednesday, June 26

Session Topic: Potency IRM Bridging and Stability Challenges

- 7:00** Session Introduction
Nadine Ritter, President, Global Biotech Experts
- 7:15** Regulatory Perspectives: Bridging Biological Relative Potency IRMs
Regulatory Invited Speaker
- 7:45** Standards Organization Perspectives: Formulation and Stability of Biological Reference Standards
Invited Speaker, NIBSC
- 8:45** Break and Audience Survey ☕
- 9:00** An Overview of Analytical Development Activities for Establishing and Maintaining Biologics Reference Standards
Isabelle Meira Silva, Associate Director, Alkermes
- 9:45** mAb Case Study on Challenges for Bridging Reference Standard Potency during Clinical Phases and Monitoring of its Stability
Vanessa Auquier, Head of Clinical Stability and Specifications, UCB
- 10:30** Break ☕
- 10:45** Panel Discussion with Q&A
- 12:00** Virtual Conference Adjourns

Join The Conversation

There's still time to be a part of the conference by submitting an abstract or registering online.

[Submit Online](#)



Virtual Conference

Managing Initial and Interim Reference Materials (IRM) for Relative Potency

June 24-28, 2024

All times are in Pacific Standard Time

Day 4 | Thursday, June 27

Session Topic: Relative Potency IRM Challenges New Modalities

- 7:00** Session Introduction
Nadine Ritter, President, Global Biotech Experts
- 7:15** Regulatory Perspectives: Relative Potency IRM for Novel Vaccines
FDA Invited Speaker, CBER, Office of Tissues and Advanced Therapies
- 7:45** Regulatory Perspectives: Relative Potency IRM for Novel Therapeutics
FDA Invited Speaker, CDER, Office of Therapeutic Biologics and Biosimilars
- 8:45** Break and Audience Survey ☕
- 9:00** Industry Case Study: Relative Potency IRM for Novel Vaccine
Industry Invited Speaker
- 9:45** Connecting the Dots: Primary and Working Reference Standards for Allogeneic CAR T Cells
Mike Sadick, Senior Director, Imugene
- 10:30** Break ☕
- 10:45** Panel Discussion with Q&A
- 11:45** Conference Closing Remarks
- 12:00** Virtual Conference Adjourns

Day 5 | Friday, June 28

Workshops: Day 2

- 7:00** Workshop 2: Cell & Gene Therapy Reference Standards
Mike Sadick, Senior Director, Imugene
Laurie Little, President, BEBPA
- 7:00** Workshop 3: Biosimilar Reference Standards
Nadine Ritter, President, Global Biotech Experts
- 9:30** Break ☕
- 12:00** Workshops Conclude

Join The Conversation

There's still time to be a part of the conference by submitting an abstract or registering online.

[Submit Online](#)